Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Iridex Corporation (IRIX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer incorporated in Delaware with principal offices in Mountain View, California, Iridex uses SEC reports to present information on its ophthalmic laser business, financial condition, and material events.
Key documents for IRIX include Form 10‑K annual reports, which describe the company’s business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for glaucoma, diabetic macular edema (DME), and other retinal diseases. Form 10‑Q quarterly reports provide interim updates on revenues from consoles, delivery devices, consumables, services, and support activities, along with segment information for its ophthalmology operations.
Iridex also files Form 8‑K current reports to announce specific events. Recent 8‑Ks have covered preliminary financial results, quarterly earnings releases, participation in investor conferences, and Nasdaq listing compliance matters, including the company’s notification of non‑compliance with Listing Rule 5550(b) and subsequent confirmation that it regained compliance with the stockholders’ equity requirement.
Investors can further review registration statements, proxy materials, and insider transaction reports such as Form 4, where applicable, to understand equity ownership and governance. On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as non‑GAAP adjusted EBITDA reconciliations, stockholders’ equity, and risk factor disclosures, allowing users to navigate Iridex’s regulatory history more efficiently.
Iridex Corp director William M. Moore received two stock option grants on June 13, 2025, as reported in this Form 4 filing:
- First grant: 53,000 stock options with exercise price of $0.94, vesting fully on either the one-year anniversary or 2026 annual meeting
- Second grant: 15,000 stock options with exercise price of $0.94, vesting monthly over four years starting July 13, 2025
Both options were granted under the company's 2008 Equity Incentive Plan and expire on June 13, 2032. The grants are exempt under Rule 16b-3. This compensation structure aligns the director's interests with shareholders through both short-term and long-term vesting schedules. The low exercise price suggests the stock may be trading near historical lows.
Iridex Corp CFO Romeo R. Dizon filed an amended Form 4 reporting two significant equity transactions on June 13, 2025:
- Acquired 22,500 Restricted Stock Units (RSUs) at $0.94 per share, with vesting over three years starting June 13, 2026 (one-third annually)
- Received stock options to purchase 75,000 shares of common stock at an exercise price of $0.94, vesting over three years and expiring June 13, 2032
Following these transactions, Dizon directly owns 37,745 shares and 75,000 stock options. This amended filing corrects a previous Form 4 filed on June 17, 2025. The equity awards were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. These grants appear to be part of executive compensation arrangements, demonstrating long-term alignment with shareholder interests through multi-year vesting schedules.
This Form 4/A amendment reports insider trading activity for Patrick Mercer, President and CEO of Iridex Corp (IRIX), correcting a filing from June 17, 2025. The transactions occurred on June 13, 2025 and include two key components:
- Restricted Stock Units (RSUs): Acquired 33,370 RSUs at $0.94 per share. These RSUs vest over three years, with one-third vesting annually starting June 13, 2026, contingent on continued service
- Stock Options: Granted rights to purchase 111,240 shares of common stock at an exercise price of $0.94 per share. These options vest over three years (one-third annually) and expire on June 13, 2032
Following these transactions, Mercer directly owns 420,100 shares. The equity awards were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. This compensation structure aligns the CEO's interests with long-term shareholder value through significant equity ownership requirements and performance incentives.